


# What science can do

**AstraZeneca Pharma India Limited**

Annual Report 2015-16





# AstraZeneca

## Welcome to AstraZeneca Pharma India Limited Annual Report 2015-2016

At AstraZeneca, each and every one of us is bold in the belief that science should be at the centre of everything we do.

Science compels us to push the boundaries of what is possible. We trust in the potential of ideas and pursue them, alone and with others, until we have transformed the treatment of disease.

### Our main therapy areas:



#### **Respiratory, Inflammation and Autoimmunity**

We have pushed the boundaries of science in respiratory disease for 40 years



#### **Cardiovascular and Metabolic diseases**

We take an integrated patient approach to reduce cardiovascular morbidity and mortality



#### **Oncology**

We are committed to advancing the science of oncology

Our values are the point of reference for our decision-making and support the creation of a strong AstraZeneca culture.



**We follow  
the science**



**We put  
patients first**



**We play  
to win**



**We do the  
right thing**



**We are  
entrepreneurial**



> Cambridge, UK



> Gaithersburg, Maryland US



> Gothenburg, Sweden

Globally we are increasing our proximity to bioscience clusters and co-locating around three strategic R&D centres.





We have a state-of-the-art, oral solid dosage manufacturing facility located in Bangalore, India.



Since 2010, AstraZenca is committed to positively impact the health of adolescents in marginalised communities in Delhi through its Young Health Programme.





We are committed to provide additional support to help patients. We have patient assistance programs in respiratory, cardiovascular and oncology in India.

# Contents

|     |   |
|-----|---|
| 10  | Notice                                  |
| 22  | Directors' Report                       |
| 41  | Management Discussion & Analysis Report |
| 47  | Report on Corporate Governance          |
| 66  | Auditors' Report                        |
| 74  | Balance Sheet                           |
| 75  | Statement of Profit and Loss            |
| 76  | Cash Flow Statement                     |
| 78  | Notes to the Financial Statements       |
| 116 | Ten Year Summary                        |



## AstraZeneca- Board of Directors



**D E Udwadia**  
Chairman



**K S Shah**




**Narayan K Seshadri**



**Sanjay Murdeshwar**  
Managing Director



**Ian Brimicombe**



**Claire-Marie O'Grady**



# AstraZeneca Pharma India Limited

---

## Board of Directors

---

Mr. D. E. Udawadia, Chairman  
Mr. K. S. Shah  
Mr. Narayan K Seshadri  
Mr. Ian Brimicombe  
Mr. Sanjay Murdeshwar, Managing Director  
Ms. Claire-Marie O'Grady (from November 6, 2015)  
Mr. Justin Ooi (upto January 11, 2016)  
Ms. Rebekah Martin (upto November 6, 2015)

## Auditors

BSR & Co. LLP, Bangalore

## Legal Advisors

Udwadia & Co., Mumbai

## Bankers

The Hongkong and Shanghai  
Banking Corporation Limited

## Corporate and Registered Office

Block N1, 12<sup>th</sup> Floor, Manyata Embassy  
Business Park, Rachenahalli, Outer Ring  
Road, Bangalore 560045

## Factory

12<sup>th</sup> Mile on Bellary Road  
Kattigenahalli Village, Yelahanka  
Bangalore 560 063

## Sales Outlets

Ahmedabad, Bangalore, Chennai, Cuttack,  
Dehradun, Delhi\*, Guwahati, Hyderabad,  
Indore, Jaipur, Kochi, Kolkata, Lucknow,  
Mumbai, Patna, Ranchi, Chandigarh,  
Panchkula and Zirakhpur

\*Company outlets (only Delhi)

---

## Committees of Directors

---

### Audit Committee

Mr. K. S. Shah, Chairman  
Mr. D. E. Udawadia  
Ms. Claire-Marie O'Grady

### Nomination & Remuneration Committee

Mr. Narayan K Seshadri, Chairman  
Mr. D. E. Udawadia  
Mr. K. S. Shah  
Mr. Ian Brimicombe

### Stakeholders' Relationship Committee

Mr. K. S. Shah, Chairman  
Mr. Sanjay Murdeshwar

### Corporate Social Responsibility Committee

Mr. Ian Brimicombe, Chairman  
Mr. D. E. Udawadia  
Mr. Sanjay Murdeshwar

### Chief Financial Officer

Mr. Rajesh Marwaha

### Legal Counsel & Company Secretary

Mr. Anantha Murthy N

**Annual General Meeting**  
**at 3.00 p.m. on Thursday, August 11, 2016**  
**at 'The Mysore Hall', ITC Gardenia, No.1,**  
**Residency Road, Bangalore - 560025**

# AstraZeneca Pharma India Limited

Registered Office: Block N1, 12<sup>th</sup> Floor, Manyata Embassy Business Park,  
Rachenahalli, Outer Ring Road, Bangalore - 560045

CIN: L24231KA1979PLC003563, Web: [www.astrazeneca.com/india](http://www.astrazeneca.com/india)

Email: [comp.secy@astrazeneca.com](mailto:comp.secy@astrazeneca.com), Tel: +91 80 67748000, Fax: +91 80 67748557

## NOTICE

**NOTICE** is hereby given that the 37<sup>th</sup> Annual General Meeting of the Members of AstraZeneca Pharma India Limited will be held on **Thursday, August 11, 2016 at 3.00 p.m. at 'The Mysore Hall', ITC Gardenia, No.1, Residency Road, Bangalore - 560025**, to transact the following business:

### ORDINARY BUSINESS

1. To receive, consider and adopt the financial statements viz., the Audited Balance Sheet as at March 31, 2016, the Audited Profit & Loss Account and the Cash Flow Statement of the Company and Explanatory Note annexed thereto or forming part of the above documents, for the financial year ended on that date and the Reports of the Board of Directors and Auditors thereon.
2. To appoint a Director in place of Mr. Sanjay Murdeshwar (holding DIN 01481811) who retires by rotation, and being eligible, offers himself for re-appointment.
3. To appoint M/s. Price Waterhouse & Co Chartered Accountants LLP (Firm Registration No. 304026E/E-300009), as Statutory Auditors of the Company in place of M/s. BSR & Co. LLP, the retiring Statutory Auditors, to hold office for a period of 5 years from the conclusion of this 37<sup>th</sup> Annual General Meeting, until the conclusion of 42<sup>nd</sup> Annual General Meeting, subject to ratification at every Annual General Meeting and to authorize the Board of Directors to fix their remuneration.

### SPECIAL BUSINESS

4. To consider and if thought fit, to convey assent or dissent to the following Ordinary Resolution:

**RESOLVED THAT** pursuant to the provisions of Section 148 and other applicable provisions, if any, of the Companies Act, 2013 ('the Act') read with the Companies (Audit and Auditors) Rules, 2014, as amended to date, payment of remuneration of ₹ 1,50,000/- (Rupees one lac fifty thousand only) plus applicable service tax and reimbursement of out-of-pocket expenses, at actuals, to M/s. Rao, Murthy & Associates, Cost Accountants, Bangalore, (Firm Registration No.000065), appointed by the Board as Cost Auditors of the Company for conducting the cost audit of the accounts for the financial year ending March 31, 2017, be and is hereby confirmed, approved and ratified.

5. To consider and if thought fit, to convey assent or dissent to the following Ordinary Resolution:

**RESOLVED THAT** subject to the provisions of Regulation 23 (4) of Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 ('the Listing Regulations'), as amended to date, approval of the Members be and is hereby granted to the following Material Related Party Transactions entered into by the Company with AstraZeneca UK Limited (AZ UK), a Related Party as defined in Section 2(76) of the Act and in the Listing Regulations, during the financial year 2015-16:

(₹ in Crores)

| Sl. No.      | Nature of Material Related Party Transactions   | Transactions Value<br>(FY 2015-16) |
|--------------|---|------------------------------------|
| 1.           | Purchase of raw materials and traded goods by the Company from AZ UK                                | 102.07                             |
| 2.           | Reimbursement by AZ UK to the Company of the cost of employees deputed by the Company outside India | 1.54                               |
| 3.           | Reimbursement by the Company to AZ UK, the cost related to overseas employees deputed in India      | 0.42                               |
| <b>Total</b> |   | <b>104.03</b>                      |